Nifty’s Pharma and Healthcare indices have gained 1.7% and 2.6% respectively in the past month, while the benchmark Nifty declined 2% in this period.
Tata Sons boardroom battle intensifies but Tata Group stocks remain unbothered. Should you buy?
Tata Sons has rejected Noel Tata’s objections to N Chandrasekaran’s reappointment, saying the board’s decision was valid and made in accordance with the company’s Articles